- Home
- KNDI vs ENTX Comparison
KNDI vs ENTX Comparison
Compare KNDI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- ENTX
- Stock Information
- Founded
- KNDI 2002
- ENTX 2010
- Country
- KNDI China
- ENTX Israel
- Employees
- KNDI N/A
- ENTX N/A
- Industry
- KNDI Auto Manufacturing
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNDI Consumer Discretionary
- ENTX Health Care
- Exchange
- KNDI Nasdaq
- ENTX Nasdaq
- Market Cap
- KNDI 142.0M
- ENTX 69.6M
- IPO Year
- KNDI N/A
- ENTX 2018
- Fundamental
- Price
- KNDI $1.46
- ENTX $1.98
- Analyst Decision
- KNDI
- ENTX Strong Buy
- Analyst Count
- KNDI 0
- ENTX 1
- Target Price
- KNDI N/A
- ENTX $10.00
- AVG Volume (30 Days)
- KNDI 317.9K
- ENTX 59.7K
- Earning Date
- KNDI 03-17-2025
- ENTX 03-18-2025
- Dividend Yield
- KNDI N/A
- ENTX N/A
- EPS Growth
- KNDI N/A
- ENTX N/A
- EPS
- KNDI N/A
- ENTX N/A
- Revenue
- KNDI $118,127,232.00
- ENTX $99,000.00
- Revenue This Year
- KNDI N/A
- ENTX N/A
- Revenue Next Year
- KNDI N/A
- ENTX N/A
- P/E Ratio
- KNDI N/A
- ENTX N/A
- Revenue Growth
- KNDI N/A
- ENTX 607.14
- 52 Week Low
- KNDI $0.89
- ENTX $1.30
- 52 Week High
- KNDI $2.98
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- KNDI 59.23
- ENTX 48.45
- Support Level
- KNDI $1.27
- ENTX $1.78
- Resistance Level
- KNDI $1.73
- ENTX $2.00
- Average True Range (ATR)
- KNDI 0.17
- ENTX 0.16
- MACD
- KNDI 0.01
- ENTX -0.01
- Stochastic Oscillator
- KNDI 51.85
- ENTX 53.85
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.